Lung cancer

Alesha Thai(University of Melbourne), Benjamin Solomon(University of Melbourne), Lecia V. Sequist(Massachusetts General Hospital), Justin F. Gainor(Massachusetts General Hospital), Rebecca S. Heist(Massachusetts General Hospital)

The Lancet

July 21, 2021

10.1016/s0140-6736(21)00312-3

Cited by 2,491

Abstract

Related Papers

Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

Denise R Aberle, Amanda M Adams, Christine D Berg et al.|New England Journal of Medicine|2011|10.9k

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al.|New England Journal of Medicine|2015|6.2k

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi et al.|Science|2007|4.5k

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Lecia V. Sequist, Belinda A. Waltman, Dora Dias‐Santagata et al.|Science Translational Medicine|2011|3.6k

Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Yasumasa Ishida, Yasutoshi Agata, Kei‐ichi Shibahara et al.|The EMBO Journal|1992|3.2k